Phase 4 N=66,228 Mortality Reduction After Oral Azithromycin Contingency: Mortality Study
Childhood Mortality
Primary: All-cause Mortality Rate in Children Aged 1-60 Months — 24.8; 26.7 deaths per 1000 person years
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=190,238 Mortality Reduction After Oral Azithromycin: Mortality Study
Childhood Mortality
Primary: All-cause Mortality Rate in Children Aged 1-60 Months — 14.6; 16.5 deaths per 1000 person-years
N/A N=354 Heart Failure and Sudden Cardiac Death Japan Registry
Heart Failure · Arrhythmias, Cardiac · Sudden Cardiac Death
Primary: Number of Participants With Ventricular Arrhythmia Associated Symptoms - ICD/CRT-D Cohorts — 3; 8 Participants
N/A N=500 Reducing Post-Hospital Mortality in HIV-infected Adults in Tanzania
HIV Infections
Primary: Number of Participant Deaths in the First 12 Months Post-hospitalization — 43; 42 Participants — p=0.91
N/A N=168 Predicting Mortality in Patients With Return of Spontaneous Circulation After Cardiac Arrest
Post-Resuscitation Syndrome · Critical Illness · Cardiac Arrest
Primary: 30-Day Mortality — 112 participants
N/A N=3,015,000 Morbid Rates After Spiriva Chronic Obstructive Pulmonary Disease (COPD) Protocol Change
Pulmonary Disease, Chronic Obstructive
Primary: Number of Hospital Admissions in Chronic Obstructive Pulmonary Disease (COPD) Patients — 665; 765 Hospitalizations — p=0.24
N/A N=1,359 An Observational Follow-Up Study of the Incidence of Cancer and Mortality in Patients From the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Trial (MK-0653A-043-10)
Cancer
Primary: Crude Rate of Newly Diagnosed Cancer-Follow-up Primary Cohort — 1.14; 2.07 per 100 participant-years
N/A N=164 Effectiveness and Clinical Outcomes of Municipal Acute Wards Versus a General Hospital
Patient Experience · Medical Emergencies · Mortality
Primary: Patient Experiences, NORPEQ — 78.7; 80.9 units on a scale
Phase 3 N=200 High Dose CVVHDF Compared to Standard Dose CVVHDF
Acute Renal Failure
Primary: Number of Participants Alive at 30 Days After Enrollment Compared Between High Dose Versus Standard Dose Continuous Venovenous Hemodiafiltration (CVVHDF) — 56; 49…
N/A N=66 Study of the Long-term Effects of Exercise on Heath Indicators in Older People
Hypertension With Complications and Secondary Hypertension · Overweight and Obesity · Lipid Metabolism Disorders
Primary: Cardiovascular Disease Risk Factors — 3; 4; 5; 7 participants
N/A N=937 Optimization of the Ambulatory Monitoring for Patients With Heart Failure by Tele-cardiology
Chronic Heart Failure
Primary: Number of All Causes Deaths and (Unplanned) Hospitalizations — 1.46; 1.30 Events — p==0.80
N/A N=3,599 An Observational Study of Patient Cohorts Who Previously Received Long-term Treatment With Pioglitazone or Placebo in Addition to Existing Antidiabetic Medications
Diabetes Mellitus, Type 2
Primary: Percentage of Participants With First Occurrence of Macro-vascular Event or Death — 58; 60.3 percentage of participants — p=0.3444
N/A N=115 Effects of Cardiac Rehabilitation (CR) on Functional Capacity and Cardiovascular Risk Factors
Cardiovascular Disease · Coronary Disease
Primary: Functional Capacity Assessed by Changes in Total Distance Walked in the Incremental Shuttle Walk Test — 488.1; 464.8; 394.0 meters
Phase 3 N=59,721 Impact of Maternal Vitamin A or Beta-Carotene Supplementation on Maternal and Infant Mortality in Bangladesh
Vitamin A Deficiency · Maternal Mortality · Infant Mortality
Primary: All-cause, Pregnancy-related Mortality — 41; 47; 50 Participants — p=0.05
N/A N=466 Mobile Critical Care Recovery Program for Acute Respiratory Failure Survivors
Acute Respiratory Failure · Post-Intensive Care Syndrome
Primary: Self Reported Quality of Life PCS: Physical Component Score at 1 Year — 36.22; 35.29 score on a scale
N/A N=5,834 European Mortality & Length Of Intensive Care Unit (ICU) Stay Evaluation (ELOISE)
Critical Illness
Primary: Vital Status at Hospital Discharge — 1232; 165 participants
N/A N=170 Verbal Autopsy of Maternal Deaths, Stillbirths, and Neonatal Deaths in BetterBirth
Perinatal Death · Neonatal Death · Stillbirth
Primary: Cause of Death — 20; 35; 56; 50 Participants
N/A N=381 Statin Discontinuation in Advanced Illness
Palliative Medicine · Cardiovascular Disease
Primary: Proportion of Deaths Within 60 Days of Enrollment. — 0.203; 0.238 proportion of deaths
N/A N=4,856 Dissemination of CVD Risk Factor Treatment Among Diabetic Patients in Safety Net Clinics
Diabetes Mellitus · Cardiovascular Diseases
Primary: Patients Indicated for ACE/ARB and Statin Who Had an Active Prescription for Both — 1279; 1318 Participants
N/A N=445 Factors Affecting Mortality in Critical Patients Admitted to Intensive Care Unit Due to Coronavirus Disease 2019
Covid19 and Mortality
Primary: Acute Physiology and Chronic Health Evaluation II Score — 13.1; 18.3 score on a scale
Phase 4 N=204 Fixed Dose Intervention Trial of New England Enhancing Survival in SMI Patients
Serious Mental Illness · Schizophrenia · Schizoaffective Disorder
Primary: Number of Participants on Adequate Cardiovascular Prevention Care (Defined as Taking a Statin and Angiotensin Medication) — 66; 8 Participants
Phase 3 N=9,809 Safety Study of Sertindole Versus Risperidone Under Normal Conditions of Use
Schizophrenia
Primary: Number of Participants With All-cause Mortality — 64; 61; 40; 44 participants — p=0.05
Phase 3 N=1,358 Vitamin D to Improve Outcomes by Leveraging Early Treatment
Acute Respiratory Distress Syndrome · Vitamin D Deficiency · Critical Illness
Primary: All-cause, All-location Mortality to Day 90 — 125; 109 Participants — p=0.26
N/A N=65,406 Cardiovascular Events in Chronic Obstructive Pulmonary Disease Patients Initiating Olodaterol or Other Long-acting beta2 Agonists
Pulmonary Disease, Chronic Obstructive
Primary: Occurrence of First Hospitalisation or Hospital Outpatient Clinic Visit for Atrial Fibrillation or Flutter (AF) — 246; 725 Events
N/A N=334 Independent Predictors of Mortality in Polytrauma Patients
Multiple Trauma
Primary: Death — 52 participants — p=< 0.001
N/A N=1,113 Renal Replacement Therapy and In-Hospital Mortality Incidence in Cardiac Surgery Associated Acute Kidney Injury
Acute Kidney Injury
Primary: Mortality — 96; 34 Participants — p=<0.0001
Phase 2 N=61 LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)
COVID · Severe Acute Respiratory Syndrome · Sars-CoV2
Primary: To Evaluate the Proportion of Subjects Alive and Free of Respiratory Failure and Free of the Need for Continued Renal Replacement Therapy (RRT) on Day 28 (as Per…
N/A N=60,893 (CONCERN) Clinical Decision Support (CDS) System
Hospital Acquired Condition
Primary: In-hospital Mortalities — 181; 265 Participants
N/A N=151 Project Bridge: Peer Health Navigator Intervention
Schizophrenia · Depression · Medical Disorders
Primary: Changed Score on SF-12 Pain Items From Baseline to 6 Months and 12 Months — -.16; .11; .19; -.18 Changed mean z-score — p=.073
Phase 4 N=2,825 A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropoietin Stimulating Agents (ESAs)
Chronic Renal Anemia
Primary: Time to Composite of All-Cause Mortality and Non-Fatal Cardiovascular Events (Myocardial Infarction, Stroke) Defined as Time Between First Dose of Study Medication and…